European Journal of Cancer

Article	Citations
Editorial Board	464
Standardization of viability assays and high-content live-cell imaging protocols for large-scale drug testing in prostate cancer PDX-derived organoids	340
Corrigendum to ‘Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review [European Jour	227
Overcoming chemoresistance in triple negative breast cancer by bromodomain inhibition	199
Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”	186
Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition	184
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma	166
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study	162
363 (PB351): Ferrous Iron Reactive (FIRE) delivery of diagnostic or therapeutic agents	141
306 (PB294): OMX-0407 a spectrum selective kinase inhibitor shows preclinical and clinical efficacy in Angiosarcoma, an indication of high unmet medical need	141
71 (PB059): The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-inhuman phase 1/2 study	140
A-222 Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment	132
A-262 Targeting the hyperactive STAT3/5 Pathway in Cutaneous T-Cell Lymphoma: superior efficacy of multi-kinase inhibitor IQDMA over conventional PUVA therapy	129
A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas	120
A-246 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation - report of 3 cases	118
A-288 Retrospective Clinicopathological Comparative Study between Hypopigmented Mycosis Fungoides and Pityriasis Lichenoides Chronica	106
84 (PB072): Discovery and characterization of potent inhibitors of the RNA editing enzyme ADAR1	105
387 (PB375): Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins	102
405 (PB393): A combination of AURK inhibitor and HDAC inhibitor can restrain Anaplastic Thyroid Cancer aggressiveness: a drug repurposing story	95
250 (PB238): In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia	92
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC	91
277 (PB265): Comparative analysis of immune responses in a 3D ex vivo patient tissue platform across diverse cancer types	87
300 (PB288): Combination of RAS(ON) Multi-Selective and G12D-Selective Inhibitors Improves Antitumor Activity and Enhances Antitumor Immunity in Preclinical Models of KRASG12D-Driven Cancers	84
272 (PB260): Establishment and evaluation of radioresistant models from patient derived tissue	84
417 (PB405): Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells	84

441 (PB429): GRC 70267, a novel first-generation small molecule degrader of IRAK-M with anti-tumor activity	82
210 (PB198): KRASmulti inhibition and checkpoint targeting therapy show strong combination potential in KRAS wild-type and KRASG12V-driven syngeneic mouse models of pancreatic cancer	79
334 (PB322): PARP1 inhibitor resistant cell line generation and DDR cell panel development	76
310 (PB298): Synergistic Anti-Tumor Effects of the Novel HDAC Inhibitor, ABT-301, with Immune Checkpoint Inhibitors in Colorectal Cancer Through Regulation of Immune Response and Anti-Angiogenesis	75
External validation and clinical utility assessment of PREDICT v2.2 prognostic model in young, node-negative, systemic treatment-naïve breast cancer patients	73
Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience	72
Macular type of primary cutaneous B-cell lymphoma: extension of the clinical and histopathological patterns	71
Spectrum of dermo-epidermic cutaneous gamma-delta lymphomas from a single center: clinical and phenotypic analysis of an heterogenous lymphoproliferative disorder	70
Impact of Oncotype DX Recurrence Score and Nottingham Prognostic Index on adjuvant treatment in patients with axillary lymph node micrometastasis in early breast cancer	70
The role of a patient with breast cancer in a multidisciplinary team – from making a decision to changing the treatment option	68
Metabolic profile associated with chemoresistance in ovarian cancer cells using metabolomics	68
Real world evidence from a Breast Screening pilot for the underprivileged: Experiences from Bruhat Bengaluru Mahanagara Palike hospitals	68
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy	67
Discovery of Essential microRNA in Prostate Cancer Cells	66
Large genome rearrangement of BRCA1/2 in BRCA mutation negative ovarian cancer patients	66
Pharmacological activation of the mitochondrial stress protease OMA1 reveals a therapeutic liability in Diffuse Large B-Cell Lymphoma	65
Systematic evaluation of label-free protein quantification pipelines in 12 mouse syngeneic models	64
Non-clinical identification and characterization of KRAS G12D inhibitors	63
In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations	62
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas	62
T cell receptor beta constant 1 as a potential marker to better assess T cell clonality in skin samples	62
Impact of establishing a genetic clinic in conjunction with clinical practice in India	61
Preoperative accelerated partial breast irradiation in locally recurrent breast cancer patients	60
Contrast-enhanced mammography (CEM) with magnetic tracer as an alternative to MRI	58
The Punjab breast cancer AI-digital project: Implementing Artificial Intelligence-based triaging at scale for population-level screening of breast cancer	58
Impact of an Online Educational Activity on Oncologists’ Knowledge and Competence Regrading the Optimal Use of Adjuvant Treatment in Breast Cancer	57
Interobserver variation in the assessment of HER2 low expression in breast cancer: can we improve by adjusting criteria? An international interobserver study	56
Clinical and Experimental investigation of AKT1/2/3 isoforms indicated non-redundant isoform specific role in driving stemness and Cisplatin resistance in TNBCs	56
The Sponsor Acknowledgment and Introduction	56
Efficiency of textile photodynamic therapy for mycosis fungoides	56
Experience of a supra-regional cutaneous lymphoma centre during the COVID-19 pandemic	55
An update on health-related quality of life from the PROCLIPI study	55
Interactions between BRD4 short, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer	54
Neoadjuvant treatment for breast cancer patients in a Venezuelan breast center. Pathologic complete response: is it worth it?	54
SNP rs10748643 within the promoter region of ENTPD1 (the gene encoding CD39) has no prognostic value in Sézary patients	54
The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies	54
Triple negative breast cancers: Rising menace in the developing world and treatment challenges	53
Home based care for terminal cancer patients: study from rural part of India	52
Local recurrence of breast cancer after mastectomy. Impact of residual tissue in cancer follow-up	52
Cancer and immunotherapy: a role for microbiota composition	51
New drugs and options can enhance patient outcomes: But can they also erode them?	51
The ULK1 inhibitor ENV-201 impairs tumor growth in KRAS-driven flank xenografts as a single agent and in combination with the KRAS inhibitor adagrasib	51
Troponin increase during immunotherapy: Not always myocarditis	50
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry	49
Perspectives on the role of “-Omics” in predicting response to immunotherapy	49
Ichthyosis associated with immune checkpoint blockade therapy: A novel cutaneous immune-related toxicity	49
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy	49
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer	49
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants	48
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands	47

Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials	47
Unexpectedly high seroprevalance of Kaposi's sarcoma-associated herpesvirus (HHV-8) in patients with stage IV melanoma	46
Quality indicators for systemic anticancer therapy services: a systematic review of metrics used to compare quality across healthcare facilities	46
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01	46
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizum	46
Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS	46
Granulomatous slack skin: clinical retrospective study of 8 cases of the Cutaneous Lymphoma French Study Group	45
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life	45
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy	45
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters	45
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies	45
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma	45
STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling,	44
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patien	44
Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab	44
Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck	44
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer	44
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis	44
10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis	44
Gene expression-based prediction of pazopanib efficacy in sarcoma	43
Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases:An ancillary study of the phase 3 CAIRO5 trial	43
Patient-led follow-up after curative colorectal cancer surgery: The primary outcome analysis of the prospective, multicentre FUTURE-primary implementation study	43
Immunotherapy for brain metastases and primary brain tumors	43
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study	42
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma	42
Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials	42
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma	42
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations	41
Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma	41
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS	41
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer	41
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice	40
Life-threatening skin reaction with Enfortumab Vedotin: Six cases	40
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164	40
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 tr	40
Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer	39
Editorial Board	39
Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System	39
Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma	39
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients	39
DNA methylation markers in the detection of hepatocellular carcinoma	39
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)	39
Letter Re: Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS	38
Recent advances and future strategies in first-line treatment of ES-SCLC	38
Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy	38
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG	38
Early versus late response to PD-1-based immunotherapy in metastatic melanoma	38
Why effect sizes are systematically larger for progression-free survival than overall survival in cancer drug trials: Prognostic scores as a way forward	37
First xenograft and cell line of primary cutaneous diffuse large B-cell lymphoma, leg type	37
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors	37
Ocular, meningeal and cerebral involvement of mycosis fungoides associated with an immunophenotypic switch from CD4+ to CD8+	37
Transcriptomic landscape of primary cutaneous diffuse large B-cell lymphoma, leg type reveals novel therapeutic clues	37
Photodynamic therapy for the treatment of primary cutaneous B-cell marginal zone lymphoma: a series of 4 patients	36
PD1 regulates T cell exhaustion phenotypes and disease aggressiveness in CTCL	36
Real-life evaluation of efficacy and tolerability of chlormethine gel in Italian centers	36
Characteristics and clinical outcomes of breast cancer patients under different modalities of breast-conserving surgery and lymph node management in China	36
Evaluation of the role of different cell populations in mycosis fungoides microenvironment as a tool for biomarker identification for disease progression and individualized therapy	35
Initial experience with targeted axillary dissection (TAD) guided by ultrasound in early-stage node positive breast cancer patients undergoing upfront surgery	35
Racial disparity and time to treatment initiation effects on survival differences in breast cancer: a DAGs-based review protocol for a systematic review of cohort studies	35
High PD1 expression H score is associated with Sézary diagnosis: study of 91 patients with erythroderma	35
Peripheral blood neutrophil/lymphocyte ratio as a prognostic factor in triple negative breast cancer	35
A multidisciplinary approach to the enhancement of quality of life of breast cancer patients in the South-west, Nigeria	35
Triple-negative breast cancer cells that survive ionizing radiation exhibit an Axl-dependent aggressive radioresistant phenotype	35
Contrast enhanced mammography in further assessment of screen-detected breast cancer	35
The microbiome of patients with breast cancer; observational study on the microbiome composition of breast cancer patients and the effects of chemotherapy treatment on the microbiome	34
Contrast Enhanced Mammography in Breast Cancer Surveillance	34
Title Page	34
Targeted axillary dissection or sentinel node biopsy after neo-adjuvant treatment in clinically node positive patients – the West of Scotland experience	34
Efficacy and safety of abemaciclib in the treatment of HR+ HER2-advanced breast cancer: real world data	34
Mode of Recurrence/ Metastasis Detection in Breast cancer survivors	33
HX301, a potent CSF1R inhibitor, suppresses tumor associated M2 macrophage (TAM), enhancing tumor immunity and causing transit tumor inhibition in syngeneic EMT-6 tumors	33
Multimodal therapy with bexarotene and extracorporeal photopheresis for T-cell cutaneous lymphomas: real-life experiences in Argentina	33
Primary cutaneous follicle center lymphoma with secondary systemic evolution	33
Editorial Board	33
Loss of RHOA impairs lenalidomide antitumor activity in mantle cell lymphoma	33
Characterisation of adaptive responses of cancer cells to oxaliplatin by analysis of leading edge genes from genes set enrichment analysis	33
Regulation of oncogenic transcription and tumor growth in pediatric cancers by the CDK9 inhibitor KB-0742	33
Is there microbial dysbiosis in CTCL? A pilot study	33
Lineage-specific regulation of PD-1 expression in early-stage hepatocellular carcinoma following 90yttrium transarterial radioembolization – Implications in treatment outcomes	32
MYC inhibition by Omomyc unveils a prognostic gene signature in Melanoma	32

Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors	32
Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: interim analysis of the German non-interventional MINT study	32
Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis	32
A novel computational pathology approach for identifying gene signatures prognostic of disease-free survival for papillary thyroid carcinomas	32
A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study	32
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer	31
An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations	31
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours	31
Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience	31
Placing the patient at the heart of discovery science	31
Letter re: Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial	31
Temporal changes in survival among adult patients with acute lymphoblastic leukaemia diagnosed in the period 1998-2020 – A Danish nationwide population-based cohort study	31
CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients	31
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies	31
Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation	31
Nivolumab induces long-term remission in a patient with fusariosis	31
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)	30
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme	30
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases	30
Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial	30
Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004)	29
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics	29
Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study	29
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)	29
5 Oral: Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lu	29
A machine learning tool for identifying non-metastatic colorectal cancer in primary care	29
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study	29
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered dise	28
294 (PB282): Suppression of Glioblastoma Progression by FDA-Approved Central Nervous System-Accumulating Drugs via Autophagy Modulation and ER Stress-Induced Apoptosis	28
100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild	28
158 (PB146): Immune Monitoring in Preclinical Tumor Mouse Models Using Spectral Analyzer Technology	28
43 (PB031): MBT-C101, a first-in-class, selective, and potent HSP90 chaperonemediated degrader of PI3Ka	28
Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study	28
444 (PB432): First-in-human phase 1 study of RGT-264, a potent hematopoietic progenitor kinase 1 (HPK1) inhibitor in patients (pts) with advanced solid tumors	28
146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies	28
Systematic nutritional screening and assessment in older patients: Rationale for its integration into oncology practice	28
26 (PB014): Development of Tumour-specific CD146 CAR-T Cells for Targeted Cancer Immunotherapy of Solid Tumours	28
237 (PB225): Targeting NOS sensitizes the NRAS-mutant melanomas to MEK inhibition and induces Immunogenic Cell Death	28
121 (PB109): TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in patients with advanced solid tumors: an update on the phase I study	28
443 (PB431): A Sub Analysis of Clinical Study of Tomaralimab, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylat	28
299 (PB287): Lomitapide enhances cytotoxic effects of temozolomide in chemoresistant glioblastoma	28
344 (PB332): Systematic assessment of ALC1 depletion as a therapeutic approach in homologous recombination deficient cells	28
Peer Review Policy for the European Journal of Cancer (EJC)	27
Reliability of patient-reported toxicities during adjuvant chemotherapy	27
Editorial Board	27
A-186 Molecular Insights into Primary Cutaneous CD30+ T-cell Lymphoproliferative Disorders: Wnt/Beta-Catenin Pathway Activation and Prognostic Role of TP53 mutations?	27
Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose–response meta-analysis	27
Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer	27
A-206 4 cases of pediatrics mycosis fungoides revealed by recalcitrant psoriatic palmoplantar keratoderma	27
A-170 Is there microbial dysbiosis in CTCL? A pilot study	27
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA	26
ERBB2 mRNA expression in HER2-low breast cancer	26
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial	26
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study	26
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience	26
Quality of life in cutaneous lymphoma varies by lymphoma type	26
Norwegian general population normative data for the European Organization for Research and Treatment of Cancer questionnaires: the Quality of Life Questionnaire-Core 30, the Sexual Health Questionnair	26
A-200 Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Update on the German non-interventional MINT study	26
Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience	26
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study	26
Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1	26
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment	25
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy	25
Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients	25
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years	25
OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis	25
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer	25
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial	25
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients	25
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas	25
Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC	25
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours	25
Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months	25
Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas	25
A-153 Primary cutaneous T-cell lymphoma not otherwise specified (NOS) uncovering a novel RAB27A variant in Griscelli syndrome type 2	25
MaThAI: A MultiModal imaging combining Mammography and Thermalytix for better prioritization of mammography scans to detect early malignancies	24
Response to letter entitled: Re: Association between endocrine therapy and cognitive decline in older women with early breast cancer: Findings from the prospective CLIMB study	24
Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles	24
Coverage and Socio-economic inequalities in breast cancer screening in Low- and Middle-Income Countries: Analysis of Demographic and Health Surveys between 2010 and 2019	24
Computerizing the first step of the two-step algorithm in dermoscopy: A convolutional neural network for differentiating melanocytic from non-melanocytic skin lesions	24
The relationship among bowel FDG-PET uptake, pathological complete response, and eating habits in breast cancer patients undergoing neoadjuvant chemotherapy	24
Circulating tumour DNA to augment PET-CT in determining clinical outcome after head and neck cancer treatment	24
Intraoperative ultrasound is accurate for guiding breast conservative surgery in non-palpable ductal carcinoma in situ of the breast	24
Liquid biopsy assessment in primary cutaneous diffuse large B-Cell lymphoma- leg type	24
Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis	24
One-step nucleic acid amplification assay in palpable and non-palpable breast tumours	24
Eliminating the Immunotoxicity of Interleukin-12 through Protease-Sensitive Masking	24
Nipple-sparing mastectomy with primary breast reconstruction: Breast cancer local recurrence according to molecular subtype	24
HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study	24
Toxicity and cosmetic outcome after Intraoperative Radiotherapy with Electrons (IOERT) to the partial breast during breast conserving surgery of breast cancer patients in early stages: First results o	23
A novel BAD phosphorylation inhibitor combined with EGFR tyrosine kinase inhibitors in EGFR-mutant lung adenocarcinoma treatment	23
ICOSL: a new diagnostic marker and a new therapeutic target using an ICOS-Fc construct in Sézary syndrome?	23
Single-cell RNA sequencing reveals race-based heterogeneity of malignant T-cells and skin microenvironment in patients with cutaneous T-cell lymphoma	23
Real-world outcomes and tolerability of mogamulizumab monotherapy and multimodality therapy for cutaneous T-cell lymphoma: results from a multicenter retrospective cohort study	23
Investigating clinical characteristics and outcomes of hypopigmented mycosis fungoides: retrospective review at a single tertiary referral center	23